Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects with early AD who complete Study M15-566 (NCT02880956), meet all inclusion criteria, and do not meet any exclusion criteria are eligible for enrollment~* Subject was compliant during participation in Study M15-566 (NCT02880956)~* Subject has an identified, reliable study partner who has frequent contact with the subject and who will provide information as to the subject's cognitive and functional abilities~Exclusion Criteria:~* The subject has any significant change in his/her medical condition since participation in Study M15-566 (NCT02880956) that could interfere with the subject's participation in Study M15-570, could place the subject at increased risk, or could confound interpretation of study results~* More than 8 weeks have elapsed since the subject received his/her last dose of study drug in Study M15-566 (NCT02880956)~* The subject is concurrently enrolled in another interventional clinical study involving a therapeutic agent with the exception of Study M15-566 (NCT02880956)

- Gender: ALL
- Minimum Age: 57 Years
- Maximum Age: 88 Years
- Healthy Volunteers: f

Study Arms:
- 300 mg/1000 mg Tilavonemab (Type: EXPERIMENTAL): Participants who received 300 mg tilavonemab in Study M15-566 receive 1000 mg tilavonemab in Study M15-570 via intravenous (IV) infusion every 4 weeks for up to 5.5 years.
- 1000 mg/1000 mg Tilavonemab (Type: EXPERIMENTAL): Participants who received 1000 mg tilavonemab in Study M15-566 continue on the same dose in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.
- 2000 mg/2000 mg Tilavonemab (Type: EXPERIMENTAL): Participants who received 2000 mg tilavonemab in Study M15-566 continue on the same dose in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.
- PBO/2000 mg Tilavonemab (Type: EXPERIMENTAL): Participants who received placebo (PBO) in Study M15-566 receive 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).